Ready 8-Ks
3
Latest filing
April 15, 2026, 7:59 PM ET
Top materiality
0.45
Event mix
other_material ×3
Sentiment
0 pos · 0 neg · 3 neu
Recent 8-K filings for QTZM
Highest-materiality recent filing
Quantumzyme Corp. changing name to Quantum Genesis AI Corp., pending regulatory approvals
- Board approved name change to Quantum Genesis AI Corp. on Nov 30, 2025; majority shareholder consented.
- Certificate of Amendment not yet filed; effective after SEC 14C process and 20-day waiting period.
-
Quantum Genesis AI confirms CEO assignment of ibuprofen synthesis patent
CEO Naveen Kulkarni assigned all rights in US Patent App. US20250146029A1 for enzymatic ibuprofen synthesis to the company.
-
Quantumzyme Corp. changes name to Quantum Genesis AI Corp., ticker to QGAI
Name change approved by holder of 79.56% voting power via written consent on Nov 30, 2025.
-
Quantumzyme Corp. changing name to Quantum Genesis AI Corp., pending regulatory approvals
Board approved name change to Quantum Genesis AI Corp. on Nov 30, 2025; majority shareholder consented.
Materiality & sentiment trend
Max materiality 0.45 · Median 0.30 · Most common event other_material